Comparative Pharmacology
Head-to-head clinical analysis: AMONDYS 45 versus EXONDYS 51.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMONDYS 45 versus EXONDYS 51.
AMONDYS 45 vs EXONDYS 51
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amondys 45 (casimersen) is a phosphorodiamidate morpholino oligomer that binds to exon 45 of dystrophin pre-mRNA, excluding it during splicing to restore the mRNA reading frame in Duchenne muscular dystrophy (DMD) patients with amenable mutations. This enables production of internally truncated but functional dystrophin protein.
Antisense oligonucleotide that binds to exon 51 of dystrophin pre-mRNA, inducing skipping of exon 51 during splicing to restore the reading frame and produce a truncated but functional dystrophin protein in patients with Duchenne muscular dystrophy (DMD) who have confirmed mutations amenable to exon 51 skipping.
Intravenous infusion over 35-60 minutes: 30 mg/kg once every 7 days.
30 mg/kg intravenously over 35-60 minutes once weekly
None Documented
None Documented
Terminal elimination half-life is approximately 3.6 hours, necessitating frequent dosing (weekly) to maintain therapeutic levels.
Terminal elimination half-life is approximately 28-32 days. This long half-life supports weekly dosing intervals.
Primarily renal, with 100% of the dose excreted as unchanged drug in urine.
Primarily eliminated via renal excretion as intact oligonucleotide. Approximately 30-40% of administered dose is excreted unchanged in urine within 24 hours. No significant biliary or fecal elimination.
Category C
Category C
Antisense Oligonucleotide
Antisense Oligonucleotide